JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chopin, P.
Right arrow Articles by Marien, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chopin, P.
Right arrow Articles by Marien, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DIAZEPAM
*SCOPOLAMINE
Medline Plus Health Information
*Memory
*Seniors' Health

Vol. 301, Issue 1, 187-196, April 2002

Effects of Acute and Subchronic Administration of Dexefaroxan, an alpha 2-Adrenoceptor Antagonist, on Memory Performance in Young Adult and Aged Rodents

Philippe Chopin, Francis C. Colpaert and Marc Marien

Centre de Recherche Pierre Fabre, Castres, France

The present study examined the influence of dexefaroxan, a potent and selective alpha 2-adrenoceptor antagonist, on cognitive performance in rodents. In young adult rats, dexefaroxan reversed the deficits induced by UK 14304 [5-bromo-N-(4,5-dihydro-1-H-imidazol-2-yl)-6-quinoxalinamine], scopolamine, and diazepam in a passive avoidance task. In this test, dexefaroxan also attenuated the spontaneous forgetting induced by a 15-week training-testing interval. Moreover, dexefaroxan, given immediately after training, increased the memory performance of rats trained with a weak electric footshock in the passive avoidance test, facilitated spatial memory processes in the Morris water maze task in rats, and increased the performance of mice in an object recognition test. Thus, dexefaroxan appears to have a promnesic effect in these tests by facilitating the processes of memory retention, rather than acquisition or other noncognitive influences. The facilitatory effects of dexefaroxan in young adult rats persisted even after a 21- to 25-day constant subcutaneous infusion by using osmotic minipumps, indicating that tolerance to the promnesic effect of the drug did not occur during this prolonged treatment interval. Furthermore, in the passive avoidance and Morris water maze tests, dexefaroxan ameliorated the age-related memory deficits of 24-month-old rats to a level that was comparable to that of young adult animals, and reversed the memory deficits induced by excitotoxin lesions of the nucleus basalis magnocellularis region. Together, these findings support a potential utility of dexefaroxan in the treatment of cognitive deficits occurring in Alzheimer's disease.


0022-3565/02/3011-0187$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Learn. Mem.Home page
B. Ferry and J. L. McGaugh
Involvement of basolateral amygdala {alpha}2-adrenoceptors in modulating consolidation of inhibitory avoidance memory
Learn. Mem., April 1, 2008; 15(4): 238 - 243.
[Abstract] [Full Text] [PDF]


Home page
Learn. Mem.Home page
A. Veyrac, V. Nguyen, M. Marien, A. Didier, and F. Jourdan
Noradrenergic control of odor recognition in a nonassociative olfactory learning task in the mouse
Learn. Mem., December 17, 2007; 14(12): 847 - 854.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Gobert, B. Di Cara, L. Cistarelli, and M. J. Millan
Piribedil Enhances Frontocortical and Hippocampal Release of Acetylcholine in Freely Moving Rats by Blockade of alpha 2A-Adrenoceptors: A Dialysis Comparison to Talipexole and Quinelorane in the Absence of Acetylcholinesterase Inhibitors
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 338 - 346.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.